Annexon Inc(ANNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 9:25 AM ET (Korea 10/29 22:25)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.15 | Insider Own | 13% | Shs Outstand | 174.6M | Perf Week | 4.66% |
| Market Cap | 0.77B | Forward P/E | - | EPS next Y | 5.96% | Insider Trans | 2.7% | Shs Float | 164.9M | Perf Month | -2.18% |
| Enterprise Value | 0.58B | PEG | - | EPS next Q | -0.28 | Inst Own | 89.78% | Short Float | 19.18% | Perf Quarter | -23.34% |
| Income | -0.20B | P/S | - | EPS this Y | 21.51% | Inst Trans | 16.83% | Short Ratio | 10.18 | Perf Half Y | -31.41% |
| Sales | 0.00B | P/B | 3.79 | EPS next 5Y | 46.37% | ROA | -79.38% | Short Interest | 31.63M | Perf YTD | -19.52% |
| Book/sh | 1.07 | P/C | 3.66 | EPS past 3/5Y | 19.69% 20.17% | ROE | -105.26% | 52W High | -43.73% ($7.18) | Perf Year | 17.1% |
| Cash/sh | 1.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -97.63% | 52W Low | 59.06% ($2.54) | Perf 3Y | 94.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 10.96% | Gross Margin | - | Volatility(W/M) | 5.92% 6.35% | Perf 5Y | -75.98% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.53 | EPS Q/Q | 19.92% | Profit Margin | - | RSI (14) | 52.14 | Recom | 1.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.53 | Sales Q/Q | - | SMA20 | 3.86% ($3.89) | Beta | 1.43 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/12 | SMA50 | -5.09% ($4.26) | Rel Volume | 1.29 | Prev Close | $3.76 |
| Employees | 96 | LT Debt/Eq | 0.12 | EPS/Sales Surpr. | -17.25% - | SMA200 | -22.96% ($5.24) | Avg Volume(3M) | 3.11M | Price | $4.04 |
| IPO | 2020/7/24 | Option/Short | Yes/Yes | Trades | 11098 | Volume | 4,011,511 | Change | 7.45% |
🧬 Annexon (ANNX) is a US clinical-stage biotech company developing next-generation immunotherapies that target the complement C1q pathway. It has multiple antibody candidates aimed at neuroinflammatory diseases such as Guillain-Barré syndrome and geographic atrophy, and is pursuing the transition to commercialization through late-stage clinical data and regulatory filings.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
Traded more than usual. That is 129% of its average volume.
ANNX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +21.5% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -76.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 89.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #182 of 594 in the industry
Based on market cap of $766M.
FAQ
What kind of company is ANNX?
ANNX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANNX?
The market cap of ANNX is approximately $766M, ranking 2,802 within its sector.
What is the 52-week high and low for ANNX?
ANNX has recorded a 52-week high of $7.18 and a low of $2.54.
